India's homegrown vaccine also showed effectiveness of 77.8% against symptomatic COVID-19 in the trial. Last month, vaccine maker AstraZeneca Plc also said its vaccine was effective against the Delta and Kappa variants, citing a study. Bharat Biotech now estimates it will make 23 million doses a month. The Phase-III data came as Ocugen Inc, which is co-developing Covaxin with Bharat Biotech for the US market, prepares to file a request for full US approval. India, with a tally of 30.45 million infections, is the second most affected nation after the United States, with 33 million.

Source: bd News24 July 03, 2021 03:33 UTC